119 related articles for article (PubMed ID: 32451793)
1. High uptake of
Oliveira D; Stegmayr C; Heinzel A; Ermert J; Neumaier B; Shah NJ; Mottaghy FM; Langen KJ; Willuweit A
EJNMMI Res; 2020 May; 10(1):55. PubMed ID: 32451793
[TBL] [Abstract][Full Text] [Related]
2. Influence of blood-brain barrier permeability on O-(2-
Stegmayr C; Bandelow U; Oliveira D; Lohmann P; Willuweit A; Filss C; Galldiks N; Lübke JH; Shah NJ; Ermert J; Langen KJ
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):408-416. PubMed ID: 27613541
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and pre-clinical evaluation of a new class of high-affinity
Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
[TBL] [Abstract][Full Text] [Related]
4. Discovery of
Zlatopolskiy BD; Endepols H; Krapf P; Guliyev M; Urusova EA; Richarz R; Hohberg M; Dietlein M; Drzezga A; Neumaier B
J Nucl Med; 2019 Jun; 60(6):817-823. PubMed ID: 30389823
[TBL] [Abstract][Full Text] [Related]
5. Influence of Bevacizumab on Blood-Brain Barrier Permeability and
Stegmayr C; Oliveira D; Niemietz N; Willuweit A; Lohmann P; Galldiks N; Shah NJ; Ermert J; Langen KJ
J Nucl Med; 2017 May; 58(5):700-705. PubMed ID: 28153956
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.
Schottelius M; Wurzer A; Wissmiller K; Beck R; Koch M; Gorpas D; Notni J; Buckle T; van Oosterom MN; Steiger K; Ntziachristos V; Schwaiger M; van Leeuwen FWB; Wester HJ
J Nucl Med; 2019 Jan; 60(1):71-78. PubMed ID: 30237214
[TBL] [Abstract][Full Text] [Related]
7. Threshold for defining PSMA-positivity prior to
Heilinger J; Weindler J; Roth KS; Krapf P; Schomäcker K; Dietlein M; Drzezga A; Kobe C
EJNMMI Res; 2023 Sep; 13(1):83. PubMed ID: 37731097
[TBL] [Abstract][Full Text] [Related]
8. Automated synthesis of [(18)F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models.
Bouvet V; Wuest M; Jans HS; Janzen N; Genady AR; Valliant JF; Benard F; Wuest F
EJNMMI Res; 2016 Dec; 6(1):40. PubMed ID: 27142881
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile.
Bouvet V; Wuest M; Bailey JJ; Bergman C; Janzen N; Valliant JF; Wuest F
Mol Imaging Biol; 2017 Dec; 19(6):923-932. PubMed ID: 28639122
[TBL] [Abstract][Full Text] [Related]
11. MR-Guided Delivery of Hydrophilic Molecular Imaging Agents Across the Blood-Brain Barrier Through Focused Ultrasound.
Airan RD; Foss CA; Ellens NP; Wang Y; Mease RC; Farahani K; Pomper MG
Mol Imaging Biol; 2017 Feb; 19(1):24-30. PubMed ID: 27481359
[TBL] [Abstract][Full Text] [Related]
12. Intraindividual Comparison of
Giesel FL; Will L; Lawal I; Lengana T; Kratochwil C; Vorster M; Neels O; Reyneke F; Haberkon U; Kopka K; Sathekge M
J Nucl Med; 2018 Jul; 59(7):1076-1080. PubMed ID: 29269569
[TBL] [Abstract][Full Text] [Related]
13. Simplified Methods for Quantification of
Jansen BHE; Yaqub M; Voortman J; Cysouw MCF; Windhorst AD; Schuit RC; Kramer GM; van den Eertwegh AJM; Schwarte LA; Hendrikse NH; Vis AN; van Moorselaar RJA; Hoekstra OS; Boellaard R; Oprea-Lager DE
J Nucl Med; 2019 Dec; 60(12):1730-1735. PubMed ID: 31000583
[TBL] [Abstract][Full Text] [Related]
14. In Vitro and In Vivo Characterization of an
Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
[TBL] [Abstract][Full Text] [Related]
15. Uptake of O-(2-[18F]fluoroethyl)-L-tyrosine in reactive astrocytosis in the vicinity of cerebral gliomas.
Piroth MD; Prasath J; Willuweit A; Stoffels G; Sellhaus B; van Osterhout A; Geisler S; Shah NJ; Eble MJ; Coenen HH; Langen KJ
Nucl Med Biol; 2013 Aug; 40(6):795-800. PubMed ID: 23769262
[TBL] [Abstract][Full Text] [Related]
16. Treatment-Related Uptake of
Geisler S; Stegmayr C; Niemitz N; Lohmann P; Rapp M; Stoffels G; Willuweit A; Galldiks N; Filss C; Sabel MC; Coenen HH; Shah NJ; Langen KJ
J Nucl Med; 2019 Oct; 60(10):1373-1379. PubMed ID: 30850492
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of experimental BT4C glioma models for somatostatin receptor 2-targeted therapies.
Kiviniemi A; Gardberg M; Autio A; Li XG; Heuser VD; Liljenbäck H; Käkelä M; Sipilä H; Kurkipuro J; Ylä-Herttuala S; Knuuti J; Minn H; Roivainen A
Acta Oncol; 2014 Aug; 53(8):1125-34. PubMed ID: 24957558
[TBL] [Abstract][Full Text] [Related]
18. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
[TBL] [Abstract][Full Text] [Related]
19. Early lesion detection with
Wondergem M; Jansen BHE; van der Zant FM; van der Sluis TM; Knol RJJ; van Kalmthout LWM; Hoekstra OS; van Moorselaar RJA; Oprea-Lager DE; Vis AN
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1911-1918. PubMed ID: 31230088
[TBL] [Abstract][Full Text] [Related]
20. Preparation of
Wang Y; Shao G; Wu J; Cui C; Zang S; Qiu F; Jia R; Wang Z; Wang F
Contrast Media Mol Imaging; 2018; 2018():8046541. PubMed ID: 29853810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
